Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab Effect on Muscle Function in XLH
NCT04146935Phase 4Completed
- Sponsor
- Yale University
- Start
- Nov 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Yale University. Started Nov 2019; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT04146935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146935.